RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer.
circulating tumor cells
gene expression
liquid biopsy
metastatic breast cancer
multiplex RT-qPCR
prognostic marker
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
14 Mar 2021
14 Mar 2021
Historique:
received:
17
02
2021
revised:
08
03
2021
accepted:
12
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
In metastatic breast cancer (MBC) the molecular characterization of circulating tumor cells (CTCs) provides a unique tool to understand metastasis-biology and therapy-resistance. We evaluated the prognostic significance of gene expression in EpCAM
Identifiants
pubmed: 33799422
pii: diagnostics11030513
doi: 10.3390/diagnostics11030513
pmc: PMC7998407
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : RESEARCH - CREATE - INNOVATE
ID : T1RCI-02935
Références
Ann Oncol. 2015 Sep;26(9):1859-1865
pubmed: 26117829
Clin Cancer Res. 2008 May 1;14(9):2593-600
pubmed: 18451221
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Matrix Biol. 2015 Apr;43:42-60
pubmed: 25728938
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Int J Cancer. 2006 Oct 1;119(7):1654-9
pubmed: 16708381
Neoplasia. 2016 Nov;18(11):647-653
pubmed: 27764697
Clin Cancer Res. 2018 Mar 15;24(6):1500-1510
pubmed: 29284708
Breast Cancer Res. 2011 Jun 10;13(3):R60
pubmed: 21663668
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Clin Chem. 2018 Jul;64(7):1054-1062
pubmed: 29769179
Nat Rev Clin Oncol. 2021 Jan 20;:
pubmed: 33473219
Breast Cancer Res Treat. 2009 Dec;118(3):523-30
pubmed: 19597704
Breast Cancer Res Treat. 2017 Dec;166(3):695-700
pubmed: 28815327
Nature. 2016 Sep 1;537(7618):102-106
pubmed: 27556950
Breast Cancer Res. 2015 Aug 19;17:113
pubmed: 26285572
Breast Cancer Res Treat. 2015 Jan;149(1):121-31
pubmed: 25432738
Ann Oncol. 2012 Jul;23(7):1744-50
pubmed: 22377561
BMC Cancer. 2016 Feb 18;16:123
pubmed: 26892682
Oncotarget. 2017 Jul 11;8(28):45544-45565
pubmed: 28489591
BMC Cancer. 2016 Jul 25;16:522
pubmed: 27456970
Cancer Lett. 2010 Feb 1;288(1):99-106
pubmed: 19619935
Cancer Discov. 2018 Oct;8(10):1286-1299
pubmed: 30104333
Eur J Cancer. 2019 Jan;106:133-143
pubmed: 30528798
Mol Oncol. 2016 Aug;10(7):1078-85
pubmed: 27178224
Cells. 2021 Jan 21;10(2):
pubmed: 33494385
Breast Cancer Res Treat. 2009 Dec;118(3):455-68
pubmed: 19115104
J Mol Diagn. 2020 Jan;22(1):111-121
pubmed: 31669227
Annu Rev Med. 2011;62:233-47
pubmed: 20887199
Mol Cancer Ther. 2019 Feb;18(2):437-447
pubmed: 30401696
Breast Cancer Res. 2019 Dec 4;21(1):137
pubmed: 31801599
Methods Mol Biol. 2015;1293:1-49
pubmed: 26040679
Breast Cancer Res. 2009;11(4):R59
pubmed: 19664291
Oncotarget. 2016 Jul 5;7(27):41677-41690
pubmed: 27223437
Adv Exp Med Biol. 2020;1220:61-80
pubmed: 32304080
Mol Oncol. 2016 Mar;10(3):431-42
pubmed: 26880168
PLoS One. 2013 Sep 18;8(9):e75038
pubmed: 24058649
Cancer Res. 2013 Jun 15;73(12):3489-93
pubmed: 23740771
BMC Cancer. 2011 Oct 04;11:422
pubmed: 21967632
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Clin Chem. 2017 Oct;63(10):1585-1593
pubmed: 28778937
Crit Rev Oncol Hematol. 2019 Feb;134:39-45
pubmed: 30771872
Cells. 2019 Jun 29;8(7):
pubmed: 31261917
JAMA Oncol. 2018 Sep 1;4(9):1179-1186
pubmed: 29955787
J Clin Med. 2020 Jul 01;9(7):
pubmed: 32630240
Nat Commun. 2017 Aug 4;8(1):196
pubmed: 28775303
Cancer Chemother Pharmacol. 2014 Dec;74(6):1217-25
pubmed: 25344760
Mol Oncol. 2019 Sep;13(9):1913-1926
pubmed: 31216110
J Clin Oncol. 2017 Jul 1;35(19):2149-2156
pubmed: 28384066